Zepbound Side Effects: Full Breakdown by Frequency

Zepbound is the obesity and sleep-apnea brand of tirzepatide, a once-weekly injection that produces some of the largest weight loss of any approved drug. It also has a real and well-documented side-effect profile, and most of it is gastrointestinal. This guide breaks down every common Zepbound side effect by how often it actually happens — using the incidence numbers straight from the FDA prescribing information — and then walks through the more serious warnings honestly, so you know what is common and mild, what is rare and serious, and where the line sits.

The numbers below come from the Zepbound label's pooled obesity trials, where side effects were recorded across the 5 mg, 10 mg, and 15 mg maintenance doses against placebo¹. That placebo comparison matters: some symptoms (like fatigue or abdominal pain) happen to people on placebo too, so the honest measure of a drug effect is how far above the placebo rate it sits.

The big picture: Zepbound side effects are GI-dominant

If you remember one thing, make it this — the overwhelming majority of Zepbound side effects are gastrointestinal, they are dose-dependent, and they cluster during the weeks when the dose is being increased rather than at a stable maintenance dose. A systematic review across the tirzepatide trial program found GI events were generally mild to moderate, scaled with the dose, were most frequent during escalation, and were the leading reason people stopped treatment⁷. An updated meta-analysis that folded in SURMOUNT-2 reached the same conclusion: strong, dose-dependent weight loss paired with a measurable rise in GI events versus placebo⁸.

That framing is the honest one. These effects are genuinely common — most people feel some nausea at some point — but for the large majority they are manageable and ease as the body adapts. They are a tradeoff, not an emergency.

Side effects ranked by frequency (FDA label)

Here is the breakdown of adverse reactions reported in at least 5% of Zepbound users in the pooled obesity trials, ordered from most to least common. Placebo rates are shown for context, and the range spans the 5 mg to 15 mg doses¹.

**Nausea — the most common.** Reported by roughly 25% to 29% of people across doses, versus about 8% on placebo¹. It is usually worst in the days after a dose increase and tends to settle once you hold at a stable dose.

**Diarrhea — about 19% to 23%**, versus roughly 8% on placebo¹. Like nausea, it is dose-related and most common during titration.

**Constipation — about 11% to 17%**, versus about 5% on placebo¹. Notably, this one is more common at the *lower* doses in the label table — slowed gastric emptying cuts both ways.

**Vomiting — about 8% to 13%**, versus 2% on placebo, and it climbs with the dose¹.

**Abdominal pain — about 9% to 10%**, versus 5% on placebo¹. Mild abdominal discomfort is common; severe, persistent, or radiating pain is not, and is a reason to call a clinician (see the pancreatitis section below).

**Dyspepsia (indigestion) — about 9% to 10%**, versus 4% on placebo¹.

**Injection-site reactions — about 6% to 8%**, versus 2% on placebo¹. Usually minor redness or irritation where the dose was given.

**Fatigue — about 5% to 7%**, versus 3% on placebo¹. The above-placebo signal is real but modest.

**Hypersensitivity reactions — about 5%**, versus 3% on placebo¹. This category covers mostly mild reactions; true anaphylaxis is a separate, rare, serious event covered below.

**Eructation (burping) — about 4% to 5%**, versus 1% on placebo¹.

**Hair loss — about 4% to 5%**, versus 1% on placebo¹. Worth a careful note: this is almost certainly not the drug attacking hair follicles directly. Rapid, large weight loss from any cause can trigger telogen effluvium, a temporary shedding phase that typically recovers — the same pattern seen after major weight loss without any drug.

**Gastroesophageal reflux (GERD) — about 4% to 5%**, versus 2% on placebo¹.

Why the dose ladder is the main defense

None of these numbers are static — they track the dose. That is exactly why Zepbound is started at 2.5 mg and raised slowly, in 2.5 mg steps no closer than four weeks apart, up to a maximum of 15 mg¹. The slow climb gives the gut time to adapt and keeps the GI effects in the "mild to moderate" band for most people. Rushing the ladder, or jumping back to a high dose after a gap, is the fastest way to turn manageable nausea into a reason to quit. The full schedule and practical tolerance tips are in our tirzepatide dosing ladder and side effects guide.

The serious warnings: rare but real

Common side effects are one thing; the label's warnings are another. These are less frequent but more consequential, and they are the reason Zepbound is prescribed and monitored by a clinician rather than sold over the counter.

**Thyroid C-cell tumors (boxed warning).** Tirzepatide caused dose-dependent thyroid C-cell tumors in rats; whether it does so in humans is unknown¹. Because of this, Zepbound is contraindicated in anyone with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2¹. This is a precaution rooted in animal data, not a confirmed human cancer signal — but it is a hard contraindication for the at-risk groups.

**Acute pancreatitis.** Pancreatitis has been reported with GLP-1-based drugs, and the Zepbound label instructs prompt evaluation if it is suspected and discontinuation if confirmed¹. The reassuring context: a tirzepatide-specific safety analysis examining pancreatitis and biliary events did not find that tirzepatide meaningfully raised pancreatitis risk over comparators in the trial data, though the signal is watched closely¹⁰. Severe, persistent abdominal pain — classically radiating to the back — warrants urgent medical attention rather than waiting for the next dose.

**Gallbladder disease.** Acute cholecystitis was reported in 0.7% of Zepbound users versus 0.2% on placebo¹. This fits a broader class pattern: a large meta-analysis of GLP-1 receptor agonist trials found a significantly increased risk of gallbladder and biliary disease, more so at higher doses and longer durations and when used for weight loss⁹. Rapid weight loss itself is an independent gallstone risk factor, so part of this is the weight loss, not only the drug.

**Hypoglycemia.** On its own in people without diabetes, Zepbound rarely causes low blood sugar. The risk rises sharply when it is combined with insulin or a sulfonylurea — in diabetes trials, hypoglycemia reached about 10% when tirzepatide was paired with a sulfonylurea¹. Anyone on those medicines needs their doses managed by a prescriber.

**Other labeled precautions.** The label also flags acute kidney injury (usually driven by dehydration from severe vomiting or diarrhea), serious hypersensitivity including rare anaphylaxis and angioedema, diabetic retinopathy complications in people with diabetes, acute gallbladder disease, and a risk of pulmonary aspiration under anesthesia because the drug slows gastric emptying — relevant if you have surgery planned¹. Severe GI reactions occurred in roughly 1.7% to 3.1% of Zepbound users versus about 1% on placebo, and the drug is not recommended in people with severe gastroparesis¹.

How this fits the efficacy tradeoff

Side effects only mean something against the benefit. In SURMOUNT-1, the pivotal obesity trial, mean weight reduction reached roughly 21% at the 15 mg dose over 72 weeks versus about 3% on placebo²; in SURMOUNT-2, adults with both obesity and type 2 diabetes still lost clinically meaningful weight³; and in the SURMOUNT-5 head-to-head, tirzepatide outperformed semaglutide 2.4 mg for weight loss⁵. Zepbound is also FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity, on the strength of the SURMOUNT-OSA trial, which showed large reductions in apnea events⁶ — see our full breakdown of Zepbound for sleep apnea. The catch the withdrawal trial made unavoidable: in SURMOUNT-4, people who stopped tirzepatide regained substantial weight while those who continued kept losing⁴. The side effects, in other words, come bundled with a drug that works — and works only while you take it. For the complete picture, see our tirzepatide evidence guide, and for how it stacks up against the other leading option, tirzepatide vs semaglutide.

The honest bottom line

Most Zepbound side effects are gastrointestinal, dose-dependent, and concentrated during dose increases: nausea (about 25-29%), diarrhea (19-23%), constipation (11-17%), and vomiting (8-13%) lead the list, with everything else under roughly 10%¹. For the large majority these are mild to moderate and ease with time and a patient dose ladder⁷. The serious warnings — thyroid C-cell tumors (animal data), pancreatitis, gallbladder disease, and hypoglycemia when combined with other diabetes drugs — are rarer but real, and they are why this is a monitored prescription medicine¹. Used the way it is labeled, with a clinician watching the dose, the profile is a manageable tradeoff for substantial, evidence-backed weight loss. To weigh your options for getting it, start with our best tirzepatide overview.